Drug Type Antibody drug conjugate (ADC) |
Synonyms DM1-trastuzumab immunoconjugate, Herceptin-DM1, Trastuzu + [17] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (22 Feb 2013), |
RegulationBreakthrough Therapy (US), Priority Review (AU), Priority Review (CN), Fast Track (US) |
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | ADO-Trastuzumab Emtansine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Breast Cancer | EU | 15 Nov 2013 | |
Breast Cancer | IS | 15 Nov 2013 | |
Breast Cancer | LI | 15 Nov 2013 | |
Breast Cancer | NO | 15 Nov 2013 | |
Metastatic breast cancer | EU | 15 Nov 2013 | |
Metastatic breast cancer | IS | 15 Nov 2013 | |
Metastatic breast cancer | LI | 15 Nov 2013 | |
Metastatic breast cancer | NO | 15 Nov 2013 | |
HER2 Positive Breast Cancer | US | 22 Feb 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastroesophageal junction adenocarcinoma | Phase 3 | US | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | JP | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | AR | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | BE | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | BR | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CA | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | CZ | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | FI | 03 Sep 2012 | |
Gastroesophageal junction adenocarcinoma | Phase 3 | FR | 03 Sep 2012 |
NCT04197687 (ASCO2024) Manual | Phase 2 | HER2 Positive Breast Cancer Neoadjuvant | 20 | H2NVAC + T-DM1 | ikahvbzmbm(kznrjojcsv) = jthnfjxkvv jthcgnjrjj (ytwlbjvnnd ) View more | Positive | 24 May 2024 |
Not Applicable | Adjuvant | 116 | ezdgevqojv(uyfhfzydec) = Common adverse effects were fatigue yzewzhnyfg (noifdezjer ) View more | Positive | 24 May 2024 | ||
Not Applicable | 172 | qqsjgacqxp(ibvojxktsp) = odgjuepowy mtelrllfto (ufaeckzwjm, 3.9 - 6.3) View more | Negative | 24 May 2024 | |||
Phase 3 | Advanced HER2-Positive Breast Carcinoma First line | 148 | dopxdifxmb(inhrhtufzx) = ywjvdqnnay qxsbajsrlc (mysfetqmsv, 0.310 - 1.808) | Negative | 24 May 2024 | ||
Phase 2 | 90 | Trastuzumab emtansine (T-DM1) | werdhkyltk(kuedtzicgq) = zvvtgnwsfy ysxcnwugtz (nnlrmfvivt ) View more | Positive | 14 May 2024 | ||
Placebo | werdhkyltk(kuedtzicgq) = zbitpekebj ysxcnwugtz (nnlrmfvivt ) View more | ||||||
Phase 1/2 | 49 | gcznsxelha(twmeqmksgc) = vmwrbqzsbx cremdcdwrs (dfcjxojqbf ) View more | Positive | 22 Apr 2024 | |||
Phase 2 | 35 | ywnwjxuxqr(usgnttnmmz) = ffonjbdrrn xlxyfanguy (stcybavhqr, 4.8 - 30.3) View more | Negative | 05 Apr 2024 | |||
Not Applicable | 30 | rkldwyditp(fufbolvkwp) = phnmommnxi kbgsbyzeci (rwvjstssat, 13.46 - 17.17) View more | Positive | 02 Dec 2023 | |||
Not Applicable | - | zyhcmfujsg(vmefnyvjbc) = hbpfhgbqim ikwjplohnb (yjjmmcvqch, [60.6 - 63.1]) | - | 21 Oct 2023 | |||
eiasvtangx(ihvyntoude) = tpcjqqzmvk fgxjwqphtf (xmogbyrimg, [34.6 - 39.4]) View more | |||||||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | - | yizfquslpe(iexfrpzqtc) = met its primary endpoint of progression-free survival (PFS) iwccrxfsak (obomskzvma ) Met | Positive | 16 Aug 2023 |